Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer

人类小细胞肺癌图谱中可塑性、转移和免疫抑制的特征

阅读:4
作者:Joseph M Chan ,Álvaro Quintanal-Villalonga ,Vianne Ran Gao ,Yubin Xie ,Viola Allaj ,Ojasvi Chaudhary ,Ignas Masilionis ,Jacklynn Egger ,Andrew Chow ,Thomas Walle ,Marissa Mattar ,Dig V K Yarlagadda ,James L Wang ,Fathema Uddin ,Michael Offin ,Metamia Ciampricotti ,Besnik Qeriqi ,Amber Bahr ,Elisa de Stanchina ,Umesh K Bhanot ,W Victoria Lai ,Matthew J Bott ,David R Jones ,Arvin Ruiz ,Marina K Baine ,Yanyun Li ,Natasha Rekhtman ,John T Poirier ,Tal Nawy ,Triparna Sen ,Linas Mazutis ,Travis J Hollmann ,Dana Pe'er ,Charles M Rudin

Abstract

Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, respectively). To define the heterogeneity of tumors and their associated microenvironments across subtypes, we sequenced 155,098 transcriptomes from 21 human biospecimens, including 54,523 SCLC transcriptomes. We observe greater tumor diversity in SCLC than lung adenocarcinoma, driven by canonical, intermediate, and admixed subtypes. We discover a PLCG2-high SCLC phenotype with stem-like, pro-metastatic features that recurs across subtypes and predicts worse overall survival. SCLC exhibits greater immune sequestration and less immune infiltration than lung adenocarcinoma, and SCLC-N shows less immune infiltrate and greater T cell dysfunction than SCLC-A. We identify a profibrotic, immunosuppressive monocyte/macrophage population in SCLC tumors that is particularly associated with the recurrent, PLCG2-high subpopulation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。